Search
Davesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigationalDavesomeran is a mRNA vaccine used in conjunction with [elasomeran] as part of the Moderna Bivalent COVID-19 vaccine. … [L43882] On November 3rd 2022, Health Canada also approved the Moderna Bivalent Vaccine as a booster shot in individuals 18 years of age or older.[L43862]
Icaridin
go.drugbank.com/drugs/DB14074InvestigationalIcaridin has been commonly used as a topically-applied insect repellent in various countries but was officially licensed for use in the United States in 2001 and Canada in 2012 [L4595]. … Icaridin was synthesized by Bayer in the 1980s based on molecular modeling [L4595].
Gepirone
go.drugbank.com/drugs/DB12184ApprovedIt was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant. … [A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder.
Streptozocin
go.drugbank.com/drugs/DB00428ApprovedInvestigationalIt is used as an antineoplastic agent and to induce diabetes in experimental animals.
Liposomal prostaglandin E1
go.drugbank.com/drugs/DB05391InvestigationalLiposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.
Piretanide
go.drugbank.com/drugs/DB02925ApprovedPiretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in
Tafluprost
go.drugbank.com/drugs/DB08819ApprovedTafluprost was approved for use in the U.S. on February 10, 2012. … A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalIt is commonly marketed as Elocta or Eloctate for intravenous injection. … Prophylaxis has also shown to reduce the formation of neutralizing anti-FVIII antibodies, or inhibitors [A31552].
Sertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnIt was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. … It has once again been approved and should soon be available on the French and Australian market.
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalIt is currently under development as topical treatment of psoriasis. … Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.